<DOC>
	<DOCNO>NCT02918266</DOCNO>
	<brief_summary>The purpose study assess effect single oral dose TAK-071 attenuation cognitive deficit induce scopolamine measure Groton Maze Learning Test ( GMLT ) ( total number error ) .</brief_summary>
	<brief_title>TAK-071 Scopolamine-Induced Cognitive Impairment Study</brief_title>
	<detailed_description>The drug test study call TAK-071 . This study look effect single oral dose TAK-071 , novel muscarinic acetylcholine receptor 1 positive allosteric modulator , scopolamine-induced deficit cognitive function healthy adult male participant . The study enroll approximately 32 participant , total 8 participant per sequence . Participants randomly assign one four treatment sequencesâ€”which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Scopolamine ; TAK-071+Scopolamine ; Placebo ; Donepezil+Scopolamine - TAK-071+Scopolamine ; Donepezil+Scopolamine ; Scopolamine ; Placebo - Donepezil+Scopolamine ; Placebo ; TAK-071+Scopolamine ; Scopolamine - Placebo ; Scopolamine ; Donepezil+Scopolamine ; TAK-071+Scopolamine The dose TAK-071 well-tolerated TAK-071-1001 study ( NCT02769065 ) select , base safety tolerability data single-rising dose ( SRD ) study . Each participant also receive scopolamine 0.5 mg , injection , subcutaneously , time Screening . This single center trial conduct United States . The overall time participate study approximately 18 week . Participants remain confined clinic 4 day intervention period . Participants contact telephone Day 72 follow-up assessment .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>1 . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 2 . Able perform CogState battery . 3 . Change Baseline ( average ) total GMLT error less equal ( &lt; = ) 5 2 hour postdose scopolamine . 4 . Sleepiness score le ( &lt; ) 8 karolinska sleepiness scale ( KSS ) 2 hour postdose scopolamine . 1 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular consumption 4 unit per day ) within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . One unit equivalent halfpint beer 1 measure spirit 1 glass wine . 2 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin Day 1 Period 1 . Cotinine test positive Screening Checkin ( Day 1 ) Period 1 . 3 . Has poor peripheral venous access . 4 . Has donate lose 450 millilitre ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 Period 1 . 5 . Is shift worker ( night , late , early result irregular bed time ) cross cross 2 time zone within 48 hour period 48 hour prior Treatment Period 1 , Day 1 end Treatment Period 4 . 6 . Reports symptoms suggest evidence current sleep disorder history sleep disorder , include limited sleep apnea , heavy snoring , primary chronic insomnia , narcolepsy restless leg syndrome , judge medical history .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>